PerkinElmer acquisition Sirion Biotech has partnered with the Center for Genomic Regulation (CRG) in Barcelona, Spain to develop adeno-associated virus (AAV) vectors for type 1 and 2 diabetes.
Viral vector-based gene therapy firm Sirion (acquired by PerkinElmer in June 2021) will use its AAV technology platform alongside international biomedical research center CRG’s knowledge of genetic regulatory mechanisms.
The goal of the partnership is to create AAV vectors that target specific pancreatic cell types and contain payloads that express therapeutic genes under control of cell-specific regulatory elements. In turn, this approach aims to increase the efficacy and safety of future AAV based gene therapies for diabetes.
Image: Stock Photo Secrets